Exploring new technologies to understand and treat neurodegenerative diseases.
Official title: Innovating next generation technologies to define mechanisms of neurodegenerative disease and devise therapeutic strategies
Funded at Stanford University · NIH-10879525 · Data updated 2026-11-12
This study is exploring how diseases like ALS and frontotemporal dementia work in the body, using cutting-edge genetic tools to find new ways to help treat these conditions, so that patients can eventually benefit from new therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | December 18, 2024 |
| Project end | November 30, 2032 |
| Funding year | 2025 |
| Award (this year) | $1,136,484 |
| NIH project number | 1R35NS137159-01 |
| Project ID | NIH-10879525 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research are individuals diagnosed with amyotrophic lateral sclerosis or frontotemporal dementia.
✕Less likely to help
Patients with neurodegenerative diseases not related to ALS or frontotemporal dementia may not receive direct benefits from this research.
What this research studies
This research focuses on understanding the biological mechanisms behind neurodegenerative diseases such as ALS and frontotemporal dementia. By utilizing advanced genetic techniques, including CRISPR/Cas9, the team aims to identify new therapeutic targets and strategies. The research involves both preclinical studies in animal models and the initiation of clinical trials to test new treatments in humans. Patients may benefit from innovative therapies that arise from these findings.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the lives of patients with neurodegenerative diseases.
How similar studies have gone: Previous research has shown promise in targeting genetic factors related to neurodegenerative diseases, indicating that this approach could lead to significant advancements.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Gitler, Aaron D. — Stanford University
- Study coordinator: Gitler, Aaron D.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.